{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:57:46Z","timestamp":1784357866423,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Substance use disorders (SUDs) are an extremely challenging category of disorders because of the high rate of relapse, lower life expectancy, important rate of psychiatric and somatic co-morbidity, lack of patients' insight during most of the disease duration, healthcare costs, etc. One of the reasons to consider these disorders very difficult for physicians and the healthcare system is the lack of adequate pharmacological agents with long-term proven efficacy. So far, there are no Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved treatments for most of the SUDs, except for alcohol use disorder, nicotine use disorder, and opioid use disorder. Immunotherapy has been considered a possible solution to SUDs because it may selectively target a certain drug of abuse, it may have a long-lasting effect (several weeks or months), and it ensures an adequate therapeutic adherence. The objective of this paper was to establish the current stage of research in the field of SUDs vaccines, based on a brief literature review. Vaccines for cocaine and nicotine dependence have reached phase III trials, while other researchers are focusing on passive immunization therapy for methamphetamine use disorder. New generations of vaccines are currently explored, and they are based on superior technologies compared to the first generation of immune therapy (e.g., viral transfer genes, more immunogenic adjuvants, or higher specificity haptens). Therefore, finding immune therapies for substance use disorders SUDs remains a matter of interest, and this approach may be useful for the management of an extremely dangerous and versatile psychiatric pathology.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.882491","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:54:47Z","timestamp":1651125287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"Octavian","family":"Vasiliu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jfda.2013.09.038","article-title":"Family and social aspects of substance use disorders and treatment","volume":"21","author":"Daley","year":"2013","journal-title":"J Food Drug Anal."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1176\/appi.ajp.2019.19121284","article-title":"Personalizing the treatment of substance use disorders","volume":"177","author":"Volkow","year":"2020","journal-title":"Am J Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/HRP.0000000000000271","article-title":"Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments","volume":"28","author":"Connery","year":"2020","journal-title":"Harv Rev Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.55453\/rjmm.2021.124.1.2","article-title":"Quality of life impairments and stress coping strategies during the Covid-19 pandemic isolation and quarantine- A web-based survey","volume":"124","author":"Vasiliu","year":"2021","journal-title":"Rom J Mil Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12916-020-01693-9","article-title":"\u201cThe post-COVID era\u201d: challenges in the treatment of substance use disorder (SUD) after the pandemic","volume":"18","author":"L\u00f3pez-Pelayo","year":"2020","journal-title":"BMC Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1360-0443.2006.01592.x","article-title":"Comorbidity between substance use disorders and psychiatric conditions","volume":"101","author":"Schuckit","year":"2006","journal-title":"Addiction."},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-244X-11-25","article-title":"Comorbid mental disorders in substance users from a single catchment area- a clinical study","volume":"11","author":"Lang\u00e5s","year":"2011","journal-title":"BMC Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/15504263.2019.1619007","article-title":"Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: a systematic review and meta-analysis","volume":"15","author":"Onyeka","year":"2019","journal-title":"J Dual Diagn."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"J Am Med Assoc."},{"key":"B10","first-page":"52","article-title":"Maintenance pharmacologic therapies for opioid use disorders: beyond opioid agonists","author":"Vasiliu","year":"2019","journal-title":"Rom J Mil Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"824936","DOI":"10.3389\/fpsyt.2021.824936","article-title":"Current status of evidence for a new diagnosis: food addiction- A literature review","volume":"12","author":"Vasiliu","year":"2022","journal-title":"Front Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction."},{"key":"B13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40263-013-0096-4","article-title":"Targeted opioid receptor antagonists in the treatment of alcohol use disorders","volume":"27","author":"Niciu","year":"2013","journal-title":"CNS Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2165\/00003495-200363040-00001","article-title":"Vaccines against drugs of abuse: a viable treatment option?","volume":"63","author":"Kantak","year":"2003","journal-title":"Drugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cbi.2012.08.015","article-title":"Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice","volume":"203","author":"Brimijoin","year":"2013","journal-title":"Chem Biol Interact."},{"key":"B17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cbi.2012.08.006","article-title":"Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage","volume":"203","author":"Gao","year":"2013","journal-title":"Chem Biol Interact."},{"key":"B18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1176\/appi.ajp.2012.12060793","article-title":"Effect of a nicotine vaccine on nicotine binding to \u03b22*-nicotinic acetylcholine receptors in vivo in human tobacco smokers","volume":"170","author":"Esterlis","year":"2013","journal-title":"Am J Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2547","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS ONE."},{"key":"B21","unstructured":"A follow-up study to assess long-term immunogenicity and safety of NicVAX\/Placebo as an aid to smoking cessation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/add.12577","article-title":"Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task","volume":"109","author":"Havermans","year":"2014","journal-title":"Addiction."},{"key":"B23","unstructured":"A Second Study of NicVAX\/Placebo as an Aid for Smoking Cessation"},{"key":"B24","unstructured":"Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies"},{"key":"B25","unstructured":"A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers"},{"key":"B26","unstructured":"Safety and Pharmacodynamics of SEL_068 Vaccine in Smokers and Non-Smokers"},{"key":"B27","unstructured":"NicVAX\/placebo as an Aid for Smoking Cessation"},{"key":"B28","unstructured":"Safety and Effectiveness of NicVAX In Treating Nicotine-Dependent Individuals"},{"key":"B29","unstructured":"Efficacy and Safety of NicVAX co-Administered With Varenicline (Champix)"},{"key":"B30","unstructured":"Improving the Efficacy of Anti-Nicotine Immunotherapy (PETNic002)"},{"key":"B31","unstructured":"Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100 \u03bcg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking"},{"key":"B32","unstructured":"Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopsych.2009.08.031","article-title":"Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans","volume":"67","author":"Haney","year":"2010","journal-title":"Biol Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen Psychiatry."},{"key":"B36","unstructured":"Safety study of a disrupted adenovirus (Ad) serotype cocaine vaccine for cocaine-dependent individuals"},{"key":"B37","unstructured":"Safety Study of Ch-mAb7F9 for Methamphetamine Abuse"},{"key":"B38","unstructured":"Safety, Tolerability, and Pharmacokinetics of IXT-m200"},{"key":"B39","unstructured":"Study of Antibody for Methamphetamine Outpatient Therapy (STAMPOUT)"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.882491\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:54:55Z","timestamp":1651125295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.882491\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":39,"alternative-id":["10.3389\/fpsyt.2022.882491"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.882491","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"882491"}}